Abstract
Mutation specific antibodies demonstrate the benefit of merging molecular findings with traditional diagnostic expertise. Whether this approach is of sustainable benefit has to be seen. Convincing data on colon carcinoma will be demonstrated at ESMO 2012 with the conclusion to screen patients for BRAFV600E for enrolment in an upcoming clinical trial combining BRAF and EGFR inhibitors.
Highlights
Cancer patients will receive targeting therapy based on knowledge of deregulated genes or signaling pathways
BRAF mutations are not restricted to melanoma [2]
V600E frequently occurs in thyroid, ovarian, coloncarcinomas, hairy cell leukemia, Langerhans cell histiocytosis, Erdheim Chester disease, pleomorphic xanthoastrocytoma and ganglioglioma
Summary
Cancer patients will receive targeting therapy based on knowledge of deregulated genes or signaling pathways. One of the current hot targets is the BRAF gene. The substance PLX4032/RG7204 [1] has shown promise in the treatment of malignant melanoma with mutations in BRAF around amino acid position 600 and the drug termed Vemurafenib/Zelboraf received FDA approval for this application. BRAF mutations are not restricted to melanoma [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
